Abstract: A device for dilating at least an obstructed portion of the urethra, includes a urinary catheter having a proximal portion and a distal portion; a dilation balloon capable of expanding radially outwardly disposed between the proximal and distal portion of the catheter; and a pressure source capable of sequentially contracting under pressure. The pressure source and dilation balloon are in fluid communication through a conduit which enables fluid to flow from the pressure source to the dilation balloon at a predetermined gradual rate when the pressure source is contracting, whereby the balloon expands gradually radially outwardly to effect the slow dilation of the urethra. A method for dilating the obstructed portion of the urethra and for treating prostatic hyperplasia is also provided.
Abstract: A device for dilating at least an obstructed portion of a urethra includes a hollow core member with opposed open ends permitting urination therethrough from the bladder, a confining covering disposed on the hollow member having a length of at least that of the obstructed portion and having hydrophilic means integrally associated therewith. The hydrophilic means is capable of absorbing water and gradually expanding for at least 30 minutes whereby the outer surface of the confining covering expands radially and outwardly, after insertion into the urethra, until dilation of the obstructed portion occurs to a desired diameter and configuration. Methods for dilating an obstructed portion of the urethra and for treating benign prostatic hyperplasia are also provided.
Type:
Grant
Filed:
April 28, 1994
Date of Patent:
March 19, 1996
Assignee:
American Medical Systems, Inc.
Inventors:
Claude Tihon, John H. Burton, Timothy C. Cook, David Rhum
Abstract: 5-(1-Hydroxy-2-piperidinopropyl)-2(1H,3H)-indolone derivatives and analogs; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.
Abstract: Certain 1-substituted 4-(1,2-benzisoxazolyl)-piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.
Abstract: A transdermal flux enhancing pharmaceutical composition for transdermal administration to a human or lower animal subject comprising a safe and effective amount of pharmacologically active compound or a prodrug thereof, an aqueous solvent system comprising from about 15 to 75% by volume of one or more water miscible solvents, and a penetration enhancer selected from certain 1-alkylazacycloheptan-2-ones and cis-olefin compounds of the formulaCH.sub.3 (CH.sub.2).sub.x CH.dbd.CH(CH.sub.2).sub.y R.sup.3where R.sup.3 is CH.sub.2 OH, CH.sub.2 NH.sub.2 or COR.sup.4 and R.sup.4 is OH or (C.sub.1 -C.sub.4)alkoxy, x and y are each an integer from 3 to 13 and the sum of x and y is from 10 to 16; methods for their use in treating various illnesses in a human or lower animal by transdermal administration of said composition.
Abstract: Antidepressant agents having the formula ##STR1## wherein R.sup.1 is a polycycloalkyl group; R.sup.2 is methyl or ethyl, X is O or NH; and Y comprises a 5- or 6-membered heterocyclic ring having one or two nitrogens; or fused bicyclic heterocyclic rings having a total of three nitrogen atoms, one in each ring and one angular nitrogen.
Type:
Grant
Filed:
March 19, 1992
Date of Patent:
March 23, 1993
Assignee:
Pfizer Inc.
Inventors:
Nicholas A. Saccomano, Fredric J. Vinick
Abstract: This invention relates to the use of certain 3-substituted-2-oxindole derivatives to inhibit interleukin-1 biosynthesis in a mammal. This invention also relates to the use of such compounds for treating interleukin-1 mediated disorders and dysfunctions such as bone and connective tissue metabolism disorders and immune dysfunction in a mammal. The methods of this invention comprise administering an interleukin-1 biosynthesis inhibiting amount of the compounds and salts of this invention to such a mammal.
Type:
Grant
Filed:
December 17, 1991
Date of Patent:
March 9, 1993
Assignee:
Pfizer Inc.
Inventors:
Carl J. Goddard, Douglas C. Hanson, Gary R. Schulte
Abstract: Diastereomeric 5R,6S-6-(1R-hydroxyethyl)-2-(1S-oxo-3R-thiolanylthio)-2-penem-3-carboxylic acid and 5R,6S-6-(1R-hydroxyethyl)-2-(1R-oxo-3S-thiolanylthio)-2-penem-3-carboxylic acid, and pharmaceutically-acceptable salts and in vivo hydrolyzable esters thereof, useful as systemic antibacterial agents; and intermediates and processes which are useful in the said synthesis of said diastereoisomers.
Abstract: An efficient, multistep process for the synthesis of certain 6-(1-hydroxyethyl) 2-substituted penem antibiotics from 2-[4R-(triphenylmethylthio)-3S-(1R-(dimethyl-t-butylsilyloxy)ethyl)-2-azet idon-1-yl]acetic acid esters.
Abstract: Combinations having synergistic anxiolytic activity which comprise a first component selected from the group consisting of 8-hydroxy-2-(dipropylamino)-1,2,3,4-tetrahydronaphthalene, gepirone, ipsapirone, tandospirone, (7S,9S)-2-(2-pyrimidyl)-7-(succinimidomethyl)-perhydro-1H-pyrido[1,2-a]pyr azine, or chlordiazepoxide; and a second component selected from the group consisting of 1-(2-pyrimidyl)pyrazine and idazoxan.
Abstract: 2-(8-Azabicyclo[3.2.1]oct-8-yl)alkanols of the formula ##STR1## wherein Q is S or CH=CH; X is H, OH or another aromatic substituent; R is hydrogen, alkyl, alkenyl or alkynyl; Y and Y.sup.1 are taken together and are arylmethylene or aralkylmethylene (or a corresponding epoxy derivative) or Y and Y.sup.1 are taken separately and Y is hydrogen or OH, and Y.sup.1 is aryl, aralkyl, arylthio, or aryloxy; and structurally related 2-(piperidino)alkanols; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.
Abstract: Compounds having the formula R-(CH.sub.2).sub.m -CO-R' wherein R is ferrocene, a 5 to 7 member azacyclic system or an 8 to 11 member azabicyclic system, having 1 or 2 nitrogen atoms, or any such system substituted with one or more of F, Cl, Br, OH, C1 to C4 alkyl, C1 to C4 alkoxy, CF.sub.3, phenyl, amino, C1 to C4 alkylamino and di(C1 to C4 alkyl)amino; m is 0 or 1; and R' is--[NH(CH.sub.2).sub.n ].sub.x NH.sub.2, with each n being independently 2 to 5 and x being 1 to 6; ##STR1## with each n being independently 2 to 5, x being 0 to 4, y and z being independently 1 to 5 and the sum of x and the greater of y and z being 1 to 5; or ##STR2## with each a being 2 to 5, each b being 2 to 5, each n being independently 2 to 5, x being 0 to 3, each y being 0 or 1, z being 0 to 3 and x+y+z being 0 to 4, and their pharmaceutically acceptable acid addition salts are potent excitatory amino acid neurotransmitter antagonists.
Type:
Grant
Filed:
August 23, 1991
Date of Patent:
February 9, 1993
Assignee:
Pfizer Inc.
Inventors:
Nicholas A. Saccomano, Robert A. Volkmann
Abstract: (C.sub.1 -C.sub.3)Alkyl-4,6,7,8,9,9a-hexahydro-2H,3H-pyrido-[1,2-a]pyrazin-1-one-7- carboxylate esters, important precursors to certain bis-aza-bicyclic anxiolytics, can be prepared from di(C.sub.1 -C.sub.3)alkyl cis-piperidine-2,5-dicarboxylate starting material by a new process via a new class of intermediates, di(C.sub.1 -C.sub.3)alkyl cis-N-(2-(phthalimido)ethyl)piperidine-2,5-dicarboxylates. In the process, the starting material is reacted with either 2-(phthalimido)ethyl triflate or 2-(phthalimido)acetaldehyde to form the new intermediate, which can then be cyclized to the aforementioned precursor.
Type:
Grant
Filed:
February 27, 1991
Date of Patent:
February 9, 1993
Assignee:
Pfizer Inc.
Inventors:
Dennis M. Godek, Charles W. Murtiashaw, Frank J. Urban, Brian C. Vanderplas
Abstract: A process and intermediates for the manufacture of S-3-methylheptanoic acid from S-citronellol; a novel crystallline form of immunoregulatory N-(S-3-methylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine, an immunoregulatory agent; and an improved process and intermediates therefor.
Abstract: Variously substituted 4-(biphen-2-ylmethylcarbamoyl)-3-hydroxybutyric acids and esters, also named as N-(biphen-2-yl)-3-hydroxyglutaramic acid derivatives, are blood cholesterol lowering agents and so are useful in the prevention and treatment of cardiovascular diseases such as atherosclerosis.
Abstract: Process and intermediates for isopropyl 3S-amino-4-cyclohexyl-2R-hydroxybutyrate and 3S-amino-2R-hydroxy-5-methylhexanoate from R-malic acid. These products are of known utility in the synthesis of certain renin inhibitors.
Abstract: Process for the production of 5-fluoro-6-chlorooxindole, (III), which is useful in the synthesis of certain analgesic and antiinflammatory agents, via two different synthetic pathways.Compounds of formula (I) and (II) shown below ##STR1## which are intermediates in the process of this invention.
Abstract: 3-Oxo-4-acyl or carbamyl-bicyclic aromatic and heterocyclic compounds as inhibitors of cyclooxygenase and lipoxygenase and useful as antiallergy and antiinflammatory agents.
Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53708. This novel antibiiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, and as a growth promotant in cattle and swine.
Type:
Grant
Filed:
June 15, 1990
Date of Patent:
October 27, 1992
Assignee:
Pfizer Inc.
Inventors:
John P. Dirlam, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone